News

  • 16 June 2020

    Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that the results of MOSAIC, the North American feasibility study of the alfapump in recurrent and refractory liver ascites, have been published in Liver Transplantation, the peer-reviewed publication of the American Association for the Study of Liver Diseases.

  • 12 June 2020

    X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today presented positive biomarker, efficacy, and safety data from its ongoing Phase 2 open-label extension trial of its lead candidate, mavorixafor, in patients with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome. The results included significant reductions in yearly infection rates and wart burden in WHIM patients treated for at least six months with mavorixafor. The data were presented in an e-poster at the 25th European Hematology Association (EHA) Annual Congress, taking place virtually from June 11-14, 2020.

  • 3 June 2020

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced U.S. Food & Drug Administration (FDA) approval of its new wireless patient Remote Control with SmartMRI ™ technology for the Axonics r-SNM® System under a premarket approval (PMA) supplement.

  • 26 May 2020

    Immunocore (or the “Company”), a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialise a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease, today announces the start of the first-in-human clinical trial of IMC-F106C, the fourth bispecific developed using the Company’s innovative ImmTAC® technology platform. Wholly owned IMC-F106C is focused on targeting tumours that express PRAME, a cancer-testis antigen (CTA) that is highly expressed in a broad range of solid and hematologic malignancies, and is being developed by Immunocore.

  • 19 May 2020

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the publication of the 1-year results from its ARTISAN-SNM study in the peer-reviewed journal Neurourology & Urodynamics (“NAU”) https://doi.org/10.1002/nau.24376. Axonics also plans to launch a multi-center registry study in the United States to collect additional real-world clinical evidence on the performance, safety and patient experience with the Axonics r-SNM® System across all approved indications to advance physician knowledge and patient access to rechargeable sacral neuromodulation therapy.